Thrombotic Thrombocytopenic Purpura - Pipeline Review, H1 2015

Published: Mar, 2015 | Pages: 53 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Thrombotic Thrombocytopenic Purpura - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Thrombotic Thrombocytopenic Purpura - Pipeline Review, H1 2015’, provides an overview of the Thrombotic Thrombocytopenic Purpura’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Thrombotic Thrombocytopenic Purpura, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombotic Thrombocytopenic Purpura and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Thrombotic Thrombocytopenic Purpura
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Thrombotic Thrombocytopenic Purpura and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Thrombotic Thrombocytopenic Purpura products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Thrombotic Thrombocytopenic Purpura pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Thrombotic Thrombocytopenic Purpura
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Thrombotic Thrombocytopenic Purpura pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Thrombotic Thrombocytopenic Purpura Overview 6
Therapeutics Development 7
Pipeline Products for Thrombotic Thrombocytopenic Purpura - Overview 7
Pipeline Products for Thrombotic Thrombocytopenic Purpura - Comparative Analysis 8
Thrombotic Thrombocytopenic Purpura - Therapeutics under Development by Companies 9
Thrombotic Thrombocytopenic Purpura - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Thrombotic Thrombocytopenic Purpura - Products under Development by Companies 13
Thrombotic Thrombocytopenic Purpura - Companies Involved in Therapeutics Development 14
Ablynx NV 14
Archemix Corp. 15
Glenmark Pharmaceuticals Ltd. 16
Kaketsuken K.K. 17
Octapharma AG 18
Omeros Corporation 19
Thrombotic Thrombocytopenic Purpura - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
ARC-15105 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
BAX-930 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
caplacizumab - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
GBR-600 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
OMS-721 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
plasma (human) - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Thrombotic Thrombocytopenic Purpura - Recent Pipeline Updates 37
Thrombotic Thrombocytopenic Purpura - Dormant Projects 42
Thrombotic Thrombocytopenic Purpura - Product Development Milestones 43
Featured News & Press Releases 43
Feb 19, 2015: Omeros Phase 2 OMS721 Trial Resulting in Extended Access for Compassionate Use 43
Dec 08, 2014: Additional Clinical Data From The Phase II Study With Ablynx'S Anti-Vwf Nanobody, Caplacizumab, Presented At The American Society Of Hematology Annual Meeting 44
Nov 26, 2014: Ablynx Demonstrates Bioequivalence Between Liquid And Lyophilised Formulations Of Its Anti Vwf nanobody, Caplacizumab 45
Jun 17, 2014: Ablynx's Anti-vWF Nanobody, Caplacizumab, achieves Clinical Proof-of-concept in Phase II Titan Study 46
Apr 03, 2014: Investigational New Drug Application Cleared by FDA for OMS721 in Thrombotic Microangiopathies 47
Jul 28, 2011: Initial Observations Of ABLYNX’S PHASE II TTP Program Presented At ISTH Congress 48
Sep 30, 2010: Ablynx Initiates Phase II Clinical Trial For ALX-0081 49
Sep 30, 2010: Ablynx Initiates Phase II Clinical Trial For Thrombotic Thrombocytopenic Purpura 50
Sep 30, 2010: Ablynx Initiates Phase II Clinical Trial For Thrombotic Thrombocytopenic Purpura 50
Aug 27, 2010: Octapharma Successfully Completes Uniplas Clinical Development 51
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 52
Disclaimer 53

List of Tables

Number of Products under Development for Thrombotic Thrombocytopenic Purpura, H1 2015 7
Number of Products under Development for Thrombotic Thrombocytopenic Purpura - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Late Stage Development, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Thrombotic Thrombocytopenic Purpura - Pipeline by Ablynx NV, H1 2015 14
Thrombotic Thrombocytopenic Purpura - Pipeline by Archemix Corp., H1 2015 15
Thrombotic Thrombocytopenic Purpura - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2015 16
Thrombotic Thrombocytopenic Purpura - Pipeline by Kaketsuken K.K., H1 2015 17
Thrombotic Thrombocytopenic Purpura - Pipeline by Octapharma AG, H1 2015 18
Thrombotic Thrombocytopenic Purpura - Pipeline by Omeros Corporation, H1 2015 19
Assessment by Monotherapy Products, H1 2015 20
Number of Products by Stage and Target, H1 2015 22
Number of Products by Stage and Mechanism of Action, H1 2015 24
Number of Products by Stage and Route of Administration, H1 2015 26
Number of Products by Stage and Molecule Type, H1 2015 28
Thrombotic Thrombocytopenic Purpura Therapeutics - Recent Pipeline Updates, H1 2015 37
Thrombotic Thrombocytopenic Purpura - Dormant Projects, H1 2015 42